{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":26,"n_cols":5,"rows_kept":26,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[15,2,15,3],[16,2,16,3],[20,2,20,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910133641603321"]
[null,null,"Titolo",null,"Apicomplexan parasites [[electronic resource] ] : molecular approaches toward targeted drug development / / edited by Katja Becker"]
[null,null,"Pubbl/distr/stampa",null,"Weinheim, : Wiley-Blackwell, c2011"]
[null,null,"ISBN",null,"1-283-83537-1"]
[{"$nulls":4},"3-527-63389-8"]
[{"$nulls":4},"3-527-63388-X"]
[null,null,"Edizione",null,"[4th ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (552 p.)"]
[null,null,"Collana",null,"Drug discovery in infectious diseases ; ; v. 2"]
[null,null,"Disciplina",null,"616.9/6"]
[null,null,"Soggetti",null,"Antiprotozoal agents"]
[{"$nulls":4},"Protozoan diseases - Chemotherapy"]
[{"$nulls":4},"Apicomplexa"]
[{"$nulls":4},"Drug development"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Apicomplexan Parasites: Molecular Approaches toward Targeted Drug Development; Foreword; Contents; Preface; List of Contributors; Part One: Screening, Bioinformatics, Chemoinformatics, and Drug Design; 1 Drug Discovery Approaches Toward Anti-Parasitic Agents; 2 New Bioinformatic Strategies Against Apicomplexan Parasites; 3 Sorting Potential Therapeutic Targets in Apicomplexa; 4 Alternatives to Drug Development in the Apicomplexa; Part Two: Metabolic Pathways and Processes Addressed by Current Drug Discovery Approaches; 5 Energy Metabolism as an Antimalarial Drug Target"]
[{"$nulls":4},"6 Polyamines in Apicomplexan Parasites7 The Reducing Milieu of Parasitized Cells as a Target of Antimalarial Agents: Methylene Blue as an Ethical Drug; 8 Lipids as Drug Targets for Malaria Therapy; 9 Targeting Apicoplast Pathways in Plasmodium; 10 Lipoic Acid Acquisition and Glutathione Biosynthesis in Apicomplexan Parasites; 11 Antimalarial Drugs and Molecules Inhibiting Hemozoin Formation; 12 Exploiting the Vitamin Metabolism of Apicomplexa as Drug Targets; 13 Vitamin Biosynthetic Pathways, the PLP Synthase Complex, and the Potential for Targeting Protein-Protein Interaction"]
[{"$nulls":4},"14 Targeting Prokaryotic Enzymes in the Eukaryotic Pathogen CryptosporidiumPart Three: Drug Targets in Apicomplexan Parasites; "]
[{"$nulls":4},"15 Novel Apicomplexan Phosphatases and Immunophilins as Domain-Specific Drug Targets; 16 Dehydrogenases and Enzymes of the Mitochondrial Electron Transport Chain as Anti-Apicomplexan Drug Targets; 17 Calcium-Dependent Protein Kinases as Drug Targets in Apicomplexan Parasites; 18 Protein Acylation: New Potential Targets for Intervention Against the Apicomplexa; 19 Drugs and Drug Targets in Neospora caninum and Related Apicomplexans; Part Four: Compounds"]
[{"$nulls":4},"20 Subversive Substrates of Glutathione Reductases from Plasmodium falciparum-Infected Red Blood Cells as Antimalarial Agents21 Ferroquine: A Concealed Weapon; 22 Current Aspects of Endoperoxides in Antiparasitic Chemotherapy; 23 Plasmodium Hsp90 as an Antimalarial Target; 24 Drug Discovery Against Babesia and Toxoplasma; 25 Search for Drugs and Drug Targets against Babesia bovis, Babesia bigemina, Babesia caballi, and Babesia (Theileria) equi; 26 Orlistat: A Repositioning Opportunity as a Growth Inhibitor of Apicomplexan Parasites?; 27 Recent Drug Discovery Against Cryptosporidium; Index"]
[null,null,null,"Sommario/riassunto","This handbook is the first dealing with the discovery of drugs directed against apicomplexan parasites. Amongst others, this group of endoparasites includes the causative agents  of Malaria, Toxoplasmosis, and Babesiosis, the latter occurring mainly in animals. Written by renowned scientific experts from academia and industry, the book focuses on currentdrug development approaches for all apicomplexan diseases making it appealing to a large audience, ranging from research labs in academia to the human and veterinarian pharmaceutical industry. This work is the second volume of the new book seri"]